Literature DB >> 11865203

Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity.

J Neuzil1, K Kågedal, L Andera, C Weber, U T Brunk.   

Abstract

The incidence of cancer and atherosclerosis, two most common causes of death in developed countries, has been stagnating or, even, increasing. Drugs effective against such conditions are needed and, in this regard, the potential anti-atherosclerotic activity of vitamin E analogs has been studied extensively. Surprisingly, recent results indicate that these agents may also exert anti-neoplastic effects. Here we review the evidence that particular analogs of vitamin E may act as both antiatherogenic and anti-cancer agents, and discuss the possible molecular bases for these actions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865203     DOI: 10.1023/a:1014378901843

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  4 in total

1.  Alpha-tocopheryl succinate induces rapid and reversible phosphatidylserine externalization in histiocytic lymphoma through the caspase-independent pathway.

Authors:  Hirofumi Fujita; Daisuke Shiva; Toshihiko Utsumi; Tetsuya Ogino; Tomohiro Ogawa; Koichi Abe; Tatsuji Yasuda; Kozo Utsumi; Junzo Sasaki
Journal:  Mol Cell Biochem       Date:  2009-07-26       Impact factor: 3.396

Review 2.  Vitamin E and breast cancer prevention: current status and future potential.

Authors:  Kimberly Kline; Karla A Lawson; Weiping Yu; Bob G Sanders
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

3.  Vitamin E analogues as inducers of apoptosis: structure-function relation.

Authors:  M Birringer; J H EyTina; B A Salvatore; J Neuzil
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

4.  Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation.

Authors:  H Dalen; J Neuzil
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.